| Literature DB >> 26977882 |
Yanxin Pei1, Kun-Wei Liu2, Jun Wang2, Alexandra Garancher2, Ran Tao3, Lourdes A Esparza2, Donna L Maier2, Yoko T Udaka4, Najiba Murad3, Sorana Morrissy5, Huriye Seker-Cin6, Sebastian Brabetz6, Lin Qi7, Mari Kogiso7, Simone Schubert8, James M Olson9, Yoon-Jae Cho8, Xiao-Nan Li7, John R Crawford10, Michael L Levy11, Marcel Kool6, Stefan M Pfister6, Michael D Taylor12, Robert J Wechsler-Reya13.
Abstract
Medulloblastoma (MB) is a highly malignant pediatric brain tumor. Despite aggressive therapy, many patients succumb to the disease, and survivors experience severe side effects from treatment. MYC-driven MB has a particularly poor prognosis and would greatly benefit from more effective therapies. We used an animal model of MYC-driven MB to screen for drugs that decrease viability of tumor cells. Among the most effective compounds were histone deacetylase inhibitors (HDACIs). HDACIs potently inhibit survival of MYC-driven MB cells in vitro, in part by inducing expression of the FOXO1 tumor suppressor gene. HDACIs also synergize with phosphatidylinositol 3-kinase inhibitors to inhibit tumor growth in vivo. These studies identify an effective combination therapy for the most aggressive form of MB.Entities:
Mesh：
Substances：
Year: 2016 PMID： 26977882 PMCID： PMC4794752 DOI： 10.1016/j.ccell.2016.02.011
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743